Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment
- 4 June 2022
- journal article
- research article
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 58 (12) , 794-801
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune featuresEuropean Respiratory Journal, 2015
- Australian Idiopathic Pulmonary Fibrosis Registry: Vital lessons from a national prospective collaborative projectRespirology, 2014
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatmentEuropean Respiratory Review, 2014
- Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort studyThe Lancet Respiratory Medicine, 2013
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Delayed Access and Survival in Idiopathic Pulmonary Fibrosis: A Cohort StudyAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011